Interrelationship of arterial calcinosis and osteoporosis. The effect of bisphosphonate therapy on the vascular wall

Aslanyan, N.S.; Бланкова, З Н; Vitsenya, M V; Mikhaylov, G.V.; Кулев, Б. Д.; Агеев, Ф Т

doi:10.18087/rhj.2016.3.2215

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Многими исследователями показана взаимосвязь аортального, артериального кальциноза, избыточного отложения кальция в атеросклеротических бляшках со снижением костной массы и остеопоротическими переломами (ОПП) костей у пациентов обоего пола [3,5,6,10].…”

Section: ââåäåíèåunclassified

“…В настоящее время установлено, что общими механизмами развития для атеросклероза, ИБС, ХСН, СД 2-го типа и ОП являются: костный морфогенный белок, регуляторная система RANKL/RANK/остеопротегерин (OPG), окисленные липопротеиды низкой плотности (ЛПНП), С-реактивный протеин, остеоиммунные модуляторы -про-воспалительные цитокины [интерлейкин-1 (ИЛ-1), ИЛ-6, ИЛ-8, фактор некроза опухоли-α (ФНО-α)], оксидативный стресс, макрофагальный колониестимулирующий фактор, дефицит эстрогенов [5,6,[11][12][13]. При атеросклерозе процесс воспаления сопровождается повреждением эндотелия, миграцией субпопуляции гладкомышечных клеток (calcifying vascular cells) во внутреннюю артериальную оболочку, активацией локальных макрофагов к фагоцитозу ЛПНП с их трансформацией в пенистые клетки, формированием атеросклеротической бляшки и развитием ишемии миокарда [10,12].…”

Section: ââåäåíèåunclassified

“…Предполагается, что у пациентов с кардиоваскулярной патологией окисленные ЛПНП могут стимулировать экспрессию моноцитарного хемотаксического фактора и макрофагального колониестимулирующего фактора эндотелиоцитами, которые вызывают дифференцировку остеокластов, приводящую к снижению минеральной плотности костной ткани с развитием ОП [6,13]. Кроме того, важную роль в патогенезе снижения минеральной плотности костной ткани может играть атеросклеротическое поражение мелких артерий микроциркуляторного русла, обеспечивающего кровоснабжение костной ткани [10,14].…”

Section: ââåäåíèåunclassified

“…Therapeutic Archive. 2019; 91 (10): 63-69. DOI: 10.26442/00403660.2019.10.000162 Контактная информация: Шилов Сергей Николаевич -д.м.н., доц.…”

Section: ââåäåíèåunclassified

“…Потенциальные патогенетические механизмы, посредством которых БФ способны уменьшать риск развития неблагоприятных сердечно-сосудистых осложнений, вызванных атеросклерозом, ИБС и ХСН, включают в себя индуцирование апоптоза макрофагов, ингибирование фагоцитоза макрофагами ЛПНП и предотвращение транс-формации их в пенистые клетки, снижение уровня ОХС путем ингибирования мевалонового пути [32]. Наблюдаемые при лечении БФ уменьшение объема бляшки и ее укрепление связывают с их позитивным влиянием на липидный спектр крови (увеличение ЛПВП и снижения атерогенных ЛПНП), а также снижением воспаления, индуцирован- ного активацией локальных макрофагов с избыточной продукцией провоспалительных цитокинов, с уменьшением выраженности оксидативного стресса [10,23]. У людей БФ этидронат изучался в нескольких исследованиях.…”

Section: îáñóAeäåíèåunclassified

See 4 more Smart Citations

The effect of bisphosphonate therapy on reducing the risk of cardiovascular complications associated with chronic heart failure, type 2 diabetes and osteoporosis in postmenopausal women

Teplyakov

Березикова

Шилов

et al. 2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To study the effectiveness of oral alendronate and ibandronate bisphosphonates for the prevention of cardiovascular complications in postmenopausal women with type 2 diabetes mellitus (DM) and osteoporosis during a 12-month prospective observation. Materials and methods. The study included 86 women with osteoporosis, chronic heart failure (CHF) and type 2 diabetes: the 1st group (n=52) included patients who received basic therapy for heart failure; the 2nd group (n=34) included patients who, in addition to the basic therapy of heart failure, were prescribed alendronic and ibandronic acid preparations for the treatment of osteoporosis. In order to identify the possibility of associating the studied factors with the nature of the course of heart failure, the patients were divided according to the results of a one - year follow - up into two subgroups: subgroup A (n=49) - patients with a favorable course of the disease and subgroup B (n=37) - patients with an unfavorable course of pathology. Results and discussion. After 12 months, a significant decrease in the levels of cerebral natriuretic peptide precursor (NT-proBNP), tumor necrosis factor-α, and interleukin-1β was found in the group of women treated with bisphosphonates compared to baseline. Significant associations of NT-proBNP levels (p=0.02) and the studied cytokines (p=0.01) with an unfavorable course of heart failure were revealed. A significant association of bisphosphonate therapy with a favorable course of heart failure (p=0.01) was also revealed. The probability of developing adverse cardiovascular events during the year in the treatment of heart failure with basic therapy drugs with additional therapy of osteoporosis with bisphosphonates is significantly (p=0.0025) lower than the treatment of patients with heart failure with only basic therapy and not taking bisphosphonates for the treatment of osteoporosis. Conclusion. In postmenopausal women with associated cardiovascular pathology (CHF, type 2 diabetes and osteoporosis), prophylactic therapy with oral alendronate and ibandronate oral bisphosphonates is effective, reduces the risk of progression of heart failure, inhibits inflammatory mediators, positively affects the combined endpoints of comorbid cardiovascular pathology.

show abstract

Section: ââåäåíèåunclassified

“…Therapeutic Archive. 2019; 91 (10): 63-69. DOI: 10.26442/00403660.2019.10.000162 Контактная информация: Шилов Сергей Николаевич -д.м.н., доц.…”

Section: ââåäåíèåunclassified

Section: îáñóAeäåíèåunclassified

See 3 more Smart Citations

The effect of bisphosphonate therapy on reducing the risk of cardiovascular complications associated with chronic heart failure, type 2 diabetes and osteoporosis in postmenopausal women

Teplyakov

Березикова

Шилов

et al. 2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

Cardioprotective effects of alendronate bisphosphonate in patients with ischemic heart disease associated with type 2 diabetes mellitus and osteoporosis

et al. 2021

View full text Add to dashboard Cite

Introduction. Diabetes mellitus, cardiovascular diseases and osteoporosis are linked by common pathophysiological mechanisms.Objective. To evaluate the effect of alendronate bisphosphonate on cardiovascular outcomes in comorbid patients with ischemic heart disease (CHD) associated with type 2 diabetes mellitus (type 2 diabetes) and osteoporosis during a two-year follow-up.Materials and methods. A total of 112 women with comorbid pathology including osteoporosis, coronary artery disease, and type 2 diabetes were examined. The patients' condition was assessed at baseline and prospectively for 24 months with a combined endpoint assessment, including: mortality, readmission for cardiovascular diseases, the development of myocardial infarction (MI), stroke, atrial fibrillation. Women were divided into groups: group 1 (n = 59) included patients who received basic therapy for IHD and type 2 diabetes, group 2 (n = 53) included patients who, in addition to basic therapy for coronary artery disease and diabetes Type 2 was prescribed alendronic acid preparation.Results and discussion. According to the results of two-year follow-up, the patients were divided into two subgroups: patients with a favorable (n = 61) and unfavorable course of coronary artery disease (n = 51). At the same time, during prospective observation, the following was assessed: the frequency of hospitalizations for cardiovascular diseases, the dynamics of the functional class (FC) of exertional angina, the development of MI, stroke, atrial fibrillation, and mortality. A significant association of alendronate therapy with a favorable course of ischemic heart disease (OR = 0.26; 95% CI = 0.18-0.57; p = 0.008), a decrease in the risk of MI (OR = 0.32; 95% CI = 0.11-0.87; p = 0.018) and worsening of FC of exertional angina (OR = 0.4; 95% CI = 0.17-0.91; p = 0.014).Conclusion. Long-term (24 months) use of alendronate is an effective and safe method for the treatment of associated cardiovascular pathology, represented by coronary artery disease, type 2 diabetes and osteoporosis in postmenopausal women, reducing the risk of MI, worsening of FC of exertional angina. These results suggest a more aggressive prescription of alendronate for osteoporotic patients at very high cardiovascular risk.

show abstract

Interrelationship of arterial calcinosis and osteoporosis. The effect of bisphosphonate therapy on the vascular wall

Cited by 2 publications

References 0 publications

The effect of bisphosphonate therapy on reducing the risk of cardiovascular complications associated with chronic heart failure, type 2 diabetes and osteoporosis in postmenopausal women

The effect of bisphosphonate therapy on reducing the risk of cardiovascular complications associated with chronic heart failure, type 2 diabetes and osteoporosis in postmenopausal women

Cardioprotective effects of alendronate bisphosphonate in patients with ischemic heart disease associated with type 2 diabetes mellitus and osteoporosis

Contact Info

Product

Resources

About